letrozole has been researched along with Lassitude in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 7.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| " This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels." | 7.76 | Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. ( Baxa, SE; Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; O'Dea, AP; Reddy, PS; Sharma, P, 2010) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 3.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| " This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels." | 3.76 | Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. ( Baxa, SE; Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; O'Dea, AP; Reddy, PS; Sharma, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ham, A | 1 |
| Kim, MH | 1 |
| Kim, GM | 1 |
| Kim, JH | 1 |
| Kim, JY | 1 |
| Park, HS | 1 |
| Park, S | 1 |
| Cho, YU | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Sohn, J | 1 |
| Safra, T | 1 |
| Kaufman, B | 1 |
| Kadouri, L | 1 |
| Efrat Ben-Baruch, N | 1 |
| Ryvo, L | 1 |
| Nisenbaum, B | 1 |
| Evron, E | 1 |
| Yerushalmi, R | 1 |
| Mao, JJ | 1 |
| Farrar, JT | 1 |
| Bruner, D | 1 |
| Zee, J | 1 |
| Bowman, M | 1 |
| Seluzicki, C | 1 |
| DeMichele, A | 1 |
| Xie, SX | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Khan, QJ | 1 |
| Reddy, PS | 1 |
| Kimler, BF | 1 |
| Sharma, P | 1 |
| Baxa, SE | 1 |
| O'Dea, AP | 1 |
| Klemp, JR | 1 |
| Fabian, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| A PHASE II Multicentric Trial Evaluating a High Dose Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer Treated by Adjuvant Chemotherapy[NCT04091178] | Phase 2 | 57 participants (Actual) | Interventional | 2013-10-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for letrozole and Lassitude
| Article | Year |
|---|---|
Everolimus Plus Letrozole for Treatment of Patients With HR
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2018 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
3 other studies available for letrozole and Lassitude
| Article | Year |
|---|---|
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Li | 2020 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuv | 2010 |